Brief: Celltrion Receives CHMP Positive Opinion For Regdanvimab
11/11/2021 22:23
Nov 11 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION RECEIVES CHMP POSITIVE OPINION FOR REGDANVIMAB
(CT-P59) AS ONE OF THE FIRST MONOCLONAL ANTIBODIES RECOMMENDED
AS A TREATMENT FOR COVID-19 BY THE CHMP
Source text for Eikon: ID:nBw7F9kfra
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares